Edition:
United Kingdom

AveXis Inc (AVXS.OQ)

AVXS.OQ on NASDAQ Stock Exchange Global Select Market

113.47USD
20 Feb 2018
Change (% chg)

-- (--)
Prev Close
$113.47
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
176,240
52-wk High
$127.15
52-wk Low
$53.94

Latest Key Developments (Source: Significant Developments)

Avexis Announces Pricing Of Public Offering Of Common Stock
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Avexis Inc ::AVEXIS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.‍PRICED AN UNDERWRITTEN PUBLIC OFFERING OF 3.92 MILLION SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $102.00 PER SHARE​.  Full Article

Avexis Announces Proposed Public Offering Of Common Stock
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Avexis Inc ::AVEXIS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.AVEXIS INC - INTENDS TO OFFER AND SELL UP TO $400 MILLION OF SHARES OF COMMON STOCK IN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Avexis Announces Expanded Clinical Development Program For AVXS-101 In Spinal Muscular Atrophy
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Avexis Inc ::AVEXIS ANNOUNCES EXPANDED CLINICAL DEVELOPMENT PROGRAM FOR AVXS-101 IN SPINAL MUSCULAR ATROPHY.AVEXIS - TO EXPAND STUDY OF AVXS-101 INTO ADDITIONAL SMA POPULATIONS INCLUDING PRE-SYMPTOMATIC, OLDER PEDIATRIC TYPE 2 AND TYPE 3 SMA PATIENTS.AVEXIS INC - ‍PLANS TO INITIATE THREE STUDIES TO FURTHER EVALUATE AVXS-101, INCLUDING IN NEW SMA PATIENT POPULATIONS​.AVEXIS INC - ‍EXPECTS TO INITIATE PIVOTAL TRIAL OF AVXS-101 IN SMA TYPE 1 IN EUROPE​ IN FIRST HALF OF 2018.  Full Article

Regenxbio And Avexis Announce Expansion Of Relationship For Spinal Muscular Atrophy treatments
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Avexis Inc ::REGENXBIO AND AVEXIS ANNOUNCE EXPANSION OF RELATIONSHIP THROUGH AMENDED LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF TREATMENTS FOR SPINAL MUSCULAR ATROPHY.REGENXBIO INC - COULD RECEIVE UP TO $260 MILLION, INCLUDING $140 MILLION IN GUARANTEED UPFRONT AND ANNUAL PAYMENTS.REGENXBIO INC - AMENDED AGREEMENT PERMITS ASSIGNMENT BY AVEXIS UPON A CHANGE OF CONTROL WITHOUT REGENXBIO'S CONSENT.REGENXBIO INC - AVEXIS ACQUIRES EXCLUSIVE RIGHTS TO ENTIRE NAV TECHNOLOGY PLATFORM FOR DEVELOPMENT OF TREATMENTS FOR SMA.REGENXBIO - FOR PRODUCT DEVELOPED FOR TREATMENT OF SMA USING NAV AAV9 VECTOR, CO WILL RECEIVE MID-SINGLE TO LOW DOUBLE-DIGIT ROYALTIES ON NET SALES.  Full Article

Avexis Inc Plans To Request A Pre-BLA Meeting For AVXS-101 In Q2 ​
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Avexis Inc ::AVEXIS ANNOUNCES ALIGNMENT WITH FDA ON NEXT STEPS TOWARD A BLA SUBMISSION FOR AVXS-101 IN SMA TYPE 1.AVEXIS INC - ‍AVEXIS PLANS TO REQUEST A PRE-BLA MEETING IN Q2 2018​.AVEXIS INC - ‍PROVIDED UPDATE FOLLOWING RECEIPT OF MINUTES FROM END-OF-PHASE 1 MEETING WITH FDA CONDUCTED ON DEC 5.AVEXIS INC SAYS PLANS TO PROVIDE AVAILABLE DATA FROM ITS ON-GOING PIVOTAL TRIAL OF AVXS-101 IN SMA TYPE 1 (STR1VE) PRIOR TO PRE-BLA MEETING.  Full Article

Avexis plans to initiate Phase 1 trial in SMA Type 2
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Avexis Inc ::AVEXIS ANNOUNCES PLAN TO INITIATE PHASE 1 TRIAL IN SMA TYPE 2 UTILIZING INTRATHECAL DELIVERY OF AVXS-101.  Full Article

Avexis posts Q3 loss per share $1.52
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Avexis Inc :Avexis reports third quarter 2017 financial and operating results.Q3 loss per share $1.52.Q3 earnings per share view $-1.54 -- Thomson Reuters I/B/E/S.Avexis Inc - cash and cash equivalents‍ $374.2 million at sept 30 2017 versus $240.4 million at dec 31, 2016​.  Full Article

Avexis Inc CFO Thomas Dee resigns
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - Avexis Inc :Avexis Inc - ‍on October 14 Thomas J. Dee resigned as senior vice president, chief financial officer - SEC filing.Avexis Inc - ‍ on October 19, 2017 board of directors of co appointed Phillip B. Donenberg as company's senior vice president, chief financial officer​.  Full Article

Avexis files for potential mixed shelf offering - SEC filing
Friday, 17 Mar 2017 

Avexis Inc :Files for potential mixed shelf offering; size not disclosed - SEC filing.  Full Article

AveXis announces proposed public offering of 4,000,000 shares of common stock
Tuesday, 6 Sep 2016 

AveXis Inc : Announces proposed public offering of 4,000,000 shares of common stock . PBM Capital Investments, Llc, an existing stockholder of AveXis, intends to offer and sell 433,526 shares in proposed offering .Avexis Inc says to offer and sell 3.6 million shares of its common stock in an underwritten public offering.  Full Article

BRIEF-Avexis To Initiate Screening For Remaining Patients In Pivotal Trial Of AVXS-101

* AVEXIS TO INITIATE SCREENING FOR REMAINING PATIENTS IN PIVOTAL TRIAL OF AVXS-101 FOR SMA TYPE 1 FOLLOWING REVIEW OF PRELIMINARY DATA FROM FIRST THREE PATIENTS Source text for Eikon: Further company coverage: